Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers
| Autor: | Christian Herzog, Rubén Ibáñez, Paul D. Clarke, Phillip Adams |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hepatitis A vaccine Injections Intramuscular Internal medicine medicine Humans Child Local Reaction Aged Pain Measurement Hepatitis A Vaccines Travel Reactogenicity business.industry Public Health Environmental and Occupational Health Hepatitis A Diary card Middle Aged medicine.disease United Kingdom Hepatitis a virus Virosome Vaccines Virosome Infectious Diseases Vaccines Inactivated Tolerability Immunology Female business |
| Zdroj: | Travel Medicine and Infectious Disease. 4:313-318 |
| ISSN: | 1477-8939 |
| DOI: | 10.1016/j.tmaid.2006.01.001 |
| Popis: | Travellers increasingly require hepatitis A virus (HAV) vaccine for overseas travel to highly endemic areas. While the inactivated HAV vaccines currently in use are all highly immunogenic, studies have shown the aluminium-free, virosome-adjuvanted vaccine Epaxal to possess a superior local tolerability profile. The objective of this study was to analyse the pattern of local reactions caused by the aluminium-free Epaxal compared with an aluminium-adjuvanted HAV vaccine.Subjects recruited from travel health centres were randomised in a 4:1 ratio to receive a single dose of either Epaxal or Havrix vaccine. Vaccinees noted adverse reactions on a 7-day diary card that was returned by mail to the centre.529 adults (or =16 years) were vaccinated, and 413 (78.1%) subjects returned diary cards, 338 (76.5%) in the Epaxal group and 75 (86.2%) in the Havrix group. Subjects reported fewer local adverse reactions for Epaxal (23.4% vs. 57.3%; p0.0001). Injection site pain categorised as Grade 2 (painful on movement) or Grade 3 (spontaneously painful) (4.7% vs. 22.7%, p=0.0001) was less frequent in the Epaxal group and resolved more quickly (or =3 days of pain, 8.6% vs. 22.7%, p=0.0001).The lower reactogenicity of the virosome-adjuvanted vaccine is an important feature for travellers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect